Instytut Immunologii I Terapii Doswiadczalnej Pan

Other

Warszawski Uniwersytet Medyczny

Narodowy Instytut Lekow

Instytut Biochemii I Biofizyki Polskiej Akademii Nauk

Instytut Immunologii I Terapii Doswiadczalnej Im. Ludwika Hirszfelda Pan We Wroclawiu

Instytut Immunolii I Terapii Doswiadczalnej Polskiej Akademii Nauk

Szkola Gowna Gospodarstwa Wiejskiego W Warzawie

Wojskowy Instytut Higieny I Epidemiologii

Andrzej Gorski

Beata Weber-Dabrowska

Andrzej Gamian

Tomasz Lipiński

Agnieszka Korzeniowska-Kowal

Ewa Zuziak

Janusz Boratyński

Monika S Hejnowicz

Agnieszka Gozdek

Joanna Empel

Magdalena Kwiatek

Grzegorz Figura

Maciej Przybylski

Romuald Gryko

Kamil Dabrowski

Agnieszka Otrowicz

Waleria Hryniewicz

Renata Jakubowska-Zahorska

Sylwia Parasion

Anna Oslizlo

Jan Borysowski

Barbara Owczarek

Marian Mulczyk

Danuta Syper

Marzanna Lusiak-Szelachowska

Malgorzata Lobocka

Krystyna Dabrowska

Agnieszka Kopciuch

Paulina Budynek

Aleksandra Glowacka

Tomasz Lipinski

The proposed method facilitates the single-stage and at the same time effective purification of phage preparations for therapeutic uses, and facilitates the maintenance of bacteriophage antibacterial activity both in the case of displacement of the bacteriophage from the resin and its proteolytic release. The protein modification of the phage capsid with appropriate binding motifs makes it possible to purify therapeutically bacteriophage strains using affinity chromatography. The proposed method is useful in the display of selected polypeptided on a bacteriophage capsid without the need to genetically modify the bacteriophage, and thus makes it possible to produce phage preparations for various uses using wild-type phages occurring naturally or others not additionally modified for phage-display purposes.

Method of producing bacteriophage preparations comprising purification using affinity chromatography

We disclose the use of a strain of bacteriophages in the manufacturing of a preparation for improving the state of health of patients infected with adenoviruses, wherein preferably the preparation produced is used for the treatment or prevention of adenoviral infections, particularly those caused by HAdV, preferably HAdV-5.

Methods of using T4 bacteriophage in treatment of adenoviral infections caused by HAdV-5

The subject of the present invention is a novel use of a nematode in the evaluation of the therapeutic efficacy of bacteriophage preparations used in, or capable of being used in the treatment of infections caused by pathogenic bacteria in humans or animals.

Method of evaluating the therapeutic efficacy of bacteriophages

A method of preparation of purified bacteriophage with increased antibacterial activity, in which from bacterial lysate of phages is obtained, advantageously in the presence of lysozyme, chelating factor and detergent, in a continuous manner with ultrafiltration on membranes, the phage containing high molecular mass preparation, devoid of bacterial cell wall and other contaminants, free of toxins and endotoxins, active in tests of bacterial lysis, which is characterized by chromatography HPLC, In SDS-PAGE electrophoresis, immunoblotting, biological tests of bacterial lysis, and is dedicated for phage therapy of bacterial infections and tumors and for production of phage deriving pharmaceutical preparations.

Purified bacteriophage, its preparation and application

The multivalent strains of bacteriophages, methods of obtaining these and their use in the treatment of bacterial infections, particularly those of drug-resistant bacterial strains, especially arising in mucoviscidosis patients, are provided.

Methods of polyvalent bacteriophage preparation for the treatment of bacterial infections

Growing community of inventors

Wroclaw, Poland

Andrzej Gorski